THU, MAY 28, 2020 12:15 CET
Episurf Medical (NASDAQ: EPIS B) has received a Notice of Allowance from the Korean Intellectual Property Office (KIPO), implying the company’s first patent approval in Korea. The patent, entitled “System and method for creating a decision support material indicating damage to an anatomical joint” covers Episurf Medical’s 3D-based damage marking technology which constitutes a central part of the Episealer® implant system as well as the Epioscopy® joint visualisation system.
“This is a core patent for Episurf’s imaging technology. We are working towards being able to launch our products in certain Asian markets and maintaining a strong IP portfolio in relevant regions is an important part of that strategy”, says Katarina Flodström, COO, Episurf Medical. 
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12.15 CEST on 28 May 2020.